Healthcare provider profile · identity verified

Linet Mirzaian, MD

Family Practice · PANORAMA CITY, CA · NPI 1841491735

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	388	149
Amlodipine Besylate	Amlodipine Besylate	313	118
Rosuvastatin Calcium	Rosuvastatin Calcium	258	100
Lisinopril	Lisinopril	206	76
Levothyroxine Sodium	Levothyroxine Sodium	201	65
Losartan Potassium	Losartan Potassium	193	77
Metformin Hcl	Metformin Hcl	187	69
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	169	66
Alendronate Sodium	Alendronate Sodium	156	62
Omeprazole	Omeprazole	146	68
Gabapentin	Gabapentin	122	56
Glipizide	Glipizide	117	46
Albuterol Sulfate Hfa	Albuterol Sulfate	98	57
Pantoprazole Sodium	Pantoprazole Sodium	72	26
Simvastatin	Simvastatin	71	25
Metformin Hcl Er	Metformin Hcl	66	25
Hydrochlorothiazide	Hydrochlorothiazide	65	34
Atenolol	Atenolol	63	23
Jardiance	Empagliflozin	63	25
Hydralazine Hcl	Hydralazine Hcl	62	26
Humulin N Kwikpen	Insulin Nph Human Isophane	59	17
Ibuprofen	Ibuprofen	54	28
Metoprolol Tartrate	Metoprolol Tartrate	54	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	20
Triamcinolone Acetonide	Triamcinolone Acetonide	49	32
Trazodone Hcl	Trazodone Hcl	48	22
Potassium Chloride	Potassium Chloride	46	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	45	15
Mirtazapine	Mirtazapine	44	21
Hydrocortisone	Hydrocortisone	43	27
Ondansetron Odt	Ondansetron	40	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	15
Estradiol	Estradiol	38	23
Ozempic	Semaglutide	37	suppressed
Famotidine	Famotidine	32	suppressed
Fenofibrate	Fenofibrate	32	14
Humulin N	Insulin Nph Human Isophane	32	12
Meloxicam	Meloxicam	31	16
Clopidogrel	Clopidogrel Bisulfate	30	11
Duloxetine Hcl	Duloxetine Hcl	29	11
Pradaxa	Dabigatran Etexilate Mesylate	29	suppressed
Sertraline Hcl	Sertraline Hcl	28	12
Allopurinol	Allopurinol	27	11
Montelukast Sodium	Montelukast Sodium	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	12
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	23	23
Spironolactone	Spironolactone	23	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Alvesco	Ciclesonide	21	12
Humulin R	Insulin Regular, Human	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	11
Bisoprolol Fumarate	Bisoprolol Fumarate	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Clonidine Hcl	Clonidine Hcl	16	suppressed
Furosemide	Furosemide	16	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	16	suppressed
Metoprolol Succinate	Metoprolol Succinate	15	suppressed
Nystatin	Nystatin	15	suppressed
Prednisone	Prednisone	15	12
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Cephalexin	Cephalexin	13	12
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error